This inventor holds 1 USPTO granted patent. Top assignee: Pharmacia Ab. Active years: 2001.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001
Title: Carl Magnus Erik Svahn: Innovator in Heparin Derivatives
Introduction
Carl Magnus Erik Svahn is a notable inventor based in Sollentuna, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of heparin derivatives. His work focuses on enhancing the efficacy and safety of anticoagulant therapies.
Latest Patents
Svahn holds a patent for "Heparin derivatives and process for the preparation thereof." This invention relates to new heparin derivatives derived from bovine or porcine heparin. These derivatives possess a molecular weight equal to or larger than standard heparin and exhibit a sulfur content that is equal to or higher than that of the starting heparin, or at least 13% w/w. The derivatives demonstrate anticoagulant activity in the anti-FXa assay of less than 10% of the standard heparin from which they were made. They also show a ratio of APTT activity over anti-FXa activity of 3-35, a reduced prolongation of bleeding time compared to the standard heparin, and an enhancement of the rate of development of coronary collaterals in dogs that is equal to or better than clinically used heparin. The invention includes processes for preparing these new heparin derivatives and their use in manufacturing medicaments for treating ischemic heart disease and related vascular disorders.
Career Highlights
Svahn is associated with Pharmacia AB, where he has contributed to innovative research and development in the pharmaceutical industry. His work has been pivotal in advancing therapeutic options for patients with vascular disorders.
Collaborations
He has collaborated with notable colleagues, including Michael Per Weber and Christer Jan Mattsson, to further enhance the research and development of heparin derivatives.
Conclusion
Carl Magnus Erik Svahn's contributions to the field of heparin derivatives represent a significant advancement in the treatment of ischemic heart disease and related conditions. His innovative work continues to impact the pharmaceutical landscape positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile